
Proud & Long India 🇮🇳 | Student of Market | RT ≠ endorsement |🎙️Podcast Host | #AI | YouTube Link 👇
New Delhi, India
Joined October 2020
- Tweets15.3K
- Following428
- Followers39.5K
- Likes134K
Prince | Accidental Investor 🇮🇳 retweeted
Following the wonderful response to my session with @unseenvalue, excited to announce a Technical Analysis Masterclass during Christmas week! Sharing a 4-book pre-reading roadmap. Let’s learn to read the markets better!
Details & books 👇
substack.com/@amitkshukla/no…
#Technical
Prince | Accidental Investor 🇮🇳 retweeted
Sector rotation is clearly underway!
Largecaps are taking the lead, while smallcaps and microcaps are still catching up.
Interesting to see how leadership is shifting across market segments.
Let's see how this unfolds over the coming weeks. 👀
Prince | Accidental Investor 🇮🇳 retweeted
Karthika Masam is on
Karthika Masam is the most sacred month for devotees of both Shiva and Vishnu, when lighting a Deepam is believed to dispel darkness within and around us. 🪔
Om Namah Sivaya
Om Namo Narayanaya
Om Arunachaleshwaraya Namah 🙏
#KarthikaMasam
RT @unseenvalue: Date: 07-Nov-2026
The Diwali Pause: Light. Learn. Think.
A quick timestamp guide for part of the session:
7:20 Divi’s La…
Prince | Accidental Investor 🇮🇳 retweeted
Are huzoor… Precision Engineering Bull boliye! 🐂
CDMO ka bull toh retirement le chuka hai ... 😂
Thank you for kind words
Candid yet enlightening with a judicious mix of much needed humour!
The 2.5+ hrs session completes the choti diwali. 🎇
Thanks @unseenvalue sir, Amit Shukla ji & Venu bhai for sparing time on a festival.
#TejaISIWale
#KyaNahiKarnaHai
#IsMoreImportant
Prince | Accidental Investor 🇮🇳 retweeted
Divi’s Labs: The Knife and the Song
antifragilethinking.substack…
Prince | Accidental Investor 🇮🇳 retweeted
Mahalakshmi, wasn’t the entire API industry supposed to have been butchered by China in the 1990s?
By that logic, Divi’s should have been dead by now. No?
The lesson is simple:
Fragile businesses die from competition.
Robust businesses adapt to it.
Antifragile businesses gain from the space vacated by the fragile ...
China didn’t kill the API industry. It revealed who was fragile.
~21:00 👇
youtu.be/s9TsV1wJSDE?t=1258
Prince | Accidental Investor 🇮🇳 retweeted
Replying to @pranavgupta2402
Thank you, Pranav. But honestly, I don't think ideas belong to anyone. If something I write or say helps someone think better, that's enough for me. The real credit belongs to the people doing the hard work of studying these businesses and getting the calls right over time. And there is always a chance that what I think I know today will turn out to be wrong tomorrow. I've had many failures 🙏
Prince | Accidental Investor 🇮🇳 retweeted
Biggest takeaway from CPHI Milan:
AI is either neutral for manufacturing, or massively positive for novel-drug manufacturing.
AI can design better molecules and get them into Phase 1 faster.
But it cannot manufacture them.
Thermo Fisher said at CPHI that frontier AI is doubling in efficiency every 5.2 months.
If that pace holds, that's roughly 64x improvement in 3 years.
Divi’s became Emperor Divi’s without AI. With AI, the sky is the limit.
Because ultimately, someone has to manufacture those novel molecules.
Patients suffering from rare and orphan diseases need medicines, not LLMs.
Prince | Accidental Investor 🇮🇳 retweeted
StockScans Weekly Video on how to use Portfolio Feature...
youtu.be/ZopEvrlJiks?si=UE0U…
🪔 Happy Diwali from Team StockScans!
This Diwali, we have something special for our StockScans Family
Our BIGGEST-EVER Diwali Offer is here! The perfect opportunity to renew your subscription or join the StockScans family.
We're delighted to announce the launch of our ALL-NEW PORTFOLIO TRACKER.
A major step towards making StockScans your one-stop destination for everything an investor needs.
Detailed walkthrough video goes live TODAY at 1 PM.
👉 Subscribe or renew here: stockscans.in/pricing
Important: This Diwali offer is available for a very limited time. Don't miss it!
Wishing you and your family prosperity, happiness and a wonderful year ahead.
Keep Learning. Keep Investing. Keep Growing.
Prince | Accidental Investor 🇮🇳 retweeted
Random follower on X - “Any views on Supriya for an unsubscribed follower?”
Of course, bhaya.
Globally, writers and authors have a strange habit of writing and publishing their views without going country by country, asking every reader for permission first.
As for the SEBI-approved advisor who needs my views to advise his clients, perhaps he should subscribe too.
Launched at 1x book.
Now 2.5x book, ₹25,000 a year.
And still very reasonable in a bull market.
Pricing will continue to improve YoY. 😄
After all, if my intellectual capital is useful enough for your advisor to borrow, surely it is valuable enough to pay for.
Everyone wants the opinion. Few want to pay for the thinking behind it.
That is not investing.
That is opinion arbitrage.
Prince | Accidental Investor 🇮🇳 retweeted
GMM Pfaudler | Q2 FY27 Concall: A turnaround taking shape, with several moving pieces to watch
Having gone through the earnings call, I believe there is considerably more to GMM Pfaudler's story than quarterly revenue and profitability.
The company is simultaneously addressing structural issues in Europe, redesigning its global manufacturing footprint, expanding into new growth markets and working on several earnings-improvement initiatives.
The next phase of GMM Pfaudler's story will be about converting these operational changes into sustainable earnings growth.
1. European restructuring: The biggest earnings-improvement lever
This remains the most important part of the turnaround.
Management is actively addressing the structural cost issues in its European operations rather than waiting for the European chemicals industry to recover.
Key developments:
- UK manufacturing facility closure completed.
- Germany has undergone workforce reduction involving more than 1,400 employees.
- Major German restructuring costs were already accounted for in FY26.
- Swiss restructuring is underway, with relatively smaller costs.
- Manufacturing activities are progressively shifting towards Poland and India wherever commercially viable.
Expected timeline:
- Q3 FY27: Initial restructuring benefits expected.
- Q4 FY27: Greater contribution from savings.
- Q1 FY28: Substantially larger impact expected.
- H2 FY27: Germany expected to achieve at least break-even.
- FY28: German operations expected to become profitable.
Management does not anticipate significant additional German restructuring costs. The difficult restructuring decisions have largely been taken. The next challenge is translating them into operating leverage and reported profitability.
2. Poland and India: A redesigned manufacturing footprint
GMM is gradually moving towards a more cost-efficient global manufacturing model.
- Western Europe: Technology, customer relationships and critical capabilities.
- Poland: Cost-competitive manufacturing for European markets.
- India: Global manufacturing base leveraging cost and engineering advantages.
The expanded Poland capacity is expected to become operational around the end of FY27 or beginning of FY28.
this is an important structural change that could improve manufacturing competitiveness and profitability over time.
3. Peptides: A potentially significant growth opportunity
One of the most exciting discussions during the call.
Approximately Rs 150 crore of peptide-related orders received from Indian customers over the last six months.
- Existing peptide technology and operating experience in Europe.
- Established installations with major pharmaceutical companies in India.
- Management sees a significant upcoming investment cycle in peptide manufacturing.
The opportunity extends beyond GLP-1 drugs into pharmaceuticals, vaccines, skincare, food and nutrition, and other biotechnology applications.
GMM is not entering an unfamiliar business. It already has technology, experience and customer relationships to capitalise on the emerging investment opportunity.
4. Diversification: Growth opportunities beyond traditional chemicals
Management highlighted several emerging opportunities across its four business divisions.
- Pharmaceuticals/CDMO: Peptides and pharmaceutical manufacturing investments.
- Nuclear power: New reactor opportunities and capability building.
- Thermal power: Initial orders for LP and SP heaters.
- Defence: European projects involving TNT and nitrocellulose for NATO-sponsored programmes.
- Semiconductors: High-purity process systems and potential opportunities in India and the US.
- Critical minerals: Rare earths and mineral-processing investments.
- Data centres/AI: Indirect opportunities through increased demand for metals, minerals and processing infrastructure.
- Petrochemicals/fertilisers: Capacity additions across India, the Middle East and Africa.
An important observation - Management is not building its growth expectations around a major recovery in traditional chemicals. Any recovery there would be additional upside.
5. Margins: Understanding the earnings potential
There is an important distinction between consolidated margins and the underlying profitability of the business.
Management indicated:
- FY27 reported EBITDA margin expectation: 10–11%.
- Adjusted EBITDA margin, excluding loss-making entities: approximately 14–15%.
- Around 80% of the business is already operating at 14–15% EBITDA margins.
- Management believes 15% core EBITDA margins are achievable even in a downcycle.
Additional improvement levers include:
- European restructuring benefits.
- Better capacity utilisation and operating leverage.
- Improved gross margins through better pricing and volumes.
- Cost optimisation across manufacturing locations.
An analyst discussed 12.5–13% aggregate EBITDA margins for next year. Management indicated that the direction was right but did not provide formal guidance.
6. Tax optimisation and refinancing: Additional earnings levers
Effective tax rate declined from approximately 45% in Q1 to 30% in Q2.
Management expects further improvements.
The objective is to bring the effective tax rate to 30% or lower, with the target range expected by FY28.
Refinancing and debt reduction
Approximately Rs 116 crore of net debt repaid during H1 FY27.
Group-wide refinancing and simplification of intercompany loans are underway.
Interest costs are expected to be lower than last year.
Management indicated that these initiatives are
progressing faster than previously anticipated.
Earnings improvement need not come entirely from revenue growth. Operating profitability, lower interest costs and tax optimisation could collectively provide a meaningful boost to PAT. The exact financial benefits, however, are yet to be quantified.
7. Investor Day: An important upcoming milestone ( which i am tracking closely)
This is something I am particularly looking forward to.
Management intends to provide a more detailed breakdown of its earnings-improvement initiatives, including:
Contribution from European restructuring.
- Operating leverage and capacity utilisation.
Cost-reduction initiatives.
- India and Poland manufacturing strategy.
- Global business structure and accountability.
- Financial restructuring and other margin-improvement levers.
- Management also indicated its intention to become more proactive in sharing measurable targets and progress.
This will be important in assessing the credibility and timing of the turnaround.
8. Order book and revenue: Growth momentum remains strong
Q2 order intake: Rs 1,198 crore, up 36% YoY and the highest quarterly intake in company history.
- Order backlog: ₹2,446 crore, up 14% YoY.
- H1 order intake: ₹2,204 crore.
- 44% of Q2 order intake came from non-traditional industries.
- Revenue growth: 18% YoY in Q2 and approximately 17% in H1.
Growth was broad-based across all four divisions and multiple geographies. Management also highlighted that newer orders have been booked at better pricing than some orders currently being executed.
FY27 revenue growth expectation remains in double digits, with reported EBITDA margin expectations of approximately 10–11%.
I see three potential drivers of earnings growth:
- Revenue growth supported by a stronger and more diversified order book.
- Margin expansion through European restructuring and operating leverage.
- PAT improvement through lower interest costs and tax optimisation.
If these initiatives progress on the indicated timelines, GMM Pfaudler could look meaningfully different over the next few quarters. My focus from here is on the rate of execution, not just the opportunity pipeline.
The Investor Day should provide a much clearer picture of the company's medium-term earnings potential and the roadmap to achieve it.
The turnaround thesis is strengthening. The next few quarters need to validate it.
This is my interpretation of the company's Q2 FY27 earnings call, not a buy or sell recommendation.
Prince | Accidental Investor 🇮🇳 retweeted
Indian CDMO - Demand has turned swiftly and Indian CDMOs are converting it into margin through operating leverage, not pricing.
Went through these concalls this week: Laurus Labs, Piramal Pharma, Sai Life Sciences, Shilpa Medicare and Symbiotec Pharmalab. Here are my learnings:
THE BIG PICTURE
Demand is super strong. Capex is now running 18–36 months ahead of revenue. FY28 is the commissioning test, not the ordering test.
CDMO IS THE GROWTH ENGINE
- Laurus small-molecule CDMO: +86% YoY (₹875 cr)
- Piramal CDMO: +36% (₹1,424 cr)
- Shilpa specialty CDMO: +36%
- Sai: CRO +28%, CDMO +20%
Base generics are crawling by comparison. Laurus ARV was flat (+0.3%). Steroid and onco API grew ~16%.
MARGINS ARE AN OPERATING-LEVERAGE STORY
Laurus gross margin held at ~63%, yet EBITDA margin jumped from 26.0% to 34.5% YoY. ROCE rose from 16.3% to 22.5%.
Piramal grew EBITDA 72% on revenue +28% and raised FY27 growth guidance to 19–20%. The CEO’s line on US sites: “the revenue is up, our fixed costs are largely not up.”
When gross margin is stable and EBITDA margin expands, that’s leverage, not one-offs. That’s the healthy pattern.
LARGE PHARMA IS GOING STRATEGIC WITH INDIA
Sai signed its second end-to-end large-pharma engagement. Pharma’s share of its CRO revenue went from 38% to 52% in one year. 19 of the top 25 pharma companies are clients.
Sai’s CEO: “almost every large pharma is thinking about how do you become strategic with a few, maybe one or two companies.”
BIOTECH FUNDING IS BACK, BUT IT’S A CYCLE
Piramal says RFPs are up meaningfully since Jan 2026, it added 22 new customers in H1, and H1 order booking beat normal seasonality.
Its CEO was candid: “Our commercial strategy is aimed at making us less exposed, but the cycle remains.”
PEPTIDES ARE THE CONSENSUS CAPEX
1. Laurus: >16,000 L SPPS, full API rather than fragments, plus a resin acquisition
2. Shilpa: “one of India’s largest” SPPS block, commissioning by end FY27, semaglutide DMF ready
3. Sai: peptide labs plus a Telangana greenfield
4. Symbiotec: insulin and GLP-1 biologics
Revenue lags. Laurus guides commercial peptide revenue around FY29.
The contrarian take came from Sai’s own CEO: “What you think exists in GLP-1 capacity is based on technology which is not sustainable long run.”
When 4 of 5 companies build the same capacity, the question shifts from “will demand come?” to “who earns a return?” Full-API capability and backward integration look like the differentiators.
ADC / BIOCONJUGATION IS THE PREMIUM NICHE, WITH PROOF
Piramal did ~$40 mn of ADC revenue in H1, growing >50%, across 4 sites.
Laurus commissioned an OEB-5 payload-linker facility. Shilpa built an integrated ADC drug-substance plant. Sai is upgrading to class-6 containment.
High value per kg and few credible players.
FERMENTATION IS THE DARK HORSE
- Symbiotec: two 10-year take-or-pay alt-protein contracts, a 750 KL block next, an insulin drug-substance contract
- Laurus: ~400–500 KL of food- and industrial-grade capacity coming online
- Shilpa: recombinant human albumin
The catch: Laurus Bio revenue fell 16% in H1. Capacity is not utilisation.
WHERE THE MONEY IS GOING (FY27–28)
- Laurus: >₹3,000 cr, then ~₹1,500 cr/yr
- Sai: ₹1,100–1,300 cr in FY27 alone
- Symbiotec: ₹200–300 cr/yr, plus ~₹1,000 cr for alt-protein phases (customer co-funded)
- Shilpa: ₹252 cr in H1, peptide spend gated on utilisation
- Piramal: Lexington fill-finish, Riverview HPAPI, Yapan Bio stake
Three funding models are emerging: balance-sheet funded (Laurus, Sai), customer co-funded take-or-pay (Symbiotec) and phased (Shilpa). They carry very different risk.
CAPEX IS RUNNING AHEAD OF CASH
- Laurus H1 operating cash flow −26%, FCF slightly negative
- Sai borrowings: ₹96 cr → ₹448 cr in 6 months
- 61% of Symbiotec’s gross block not yet earning revenue
- Piramal net debt/EBITDA at 3.4x
Sai’s CFO: “we do not have a complete commitment on any plant.”
COMPANY IN ONE LINE EACH
1. Laurus: the execution benchmark
2. Piramal: operating leverage on an under-used global network, with tax and debt noise
3. Sai: steady compounder, now levering up
4. Shilpa: many engines on OpLev
5. Symbiotec: steady steroid API base funding 3 big bets
BIGGEST POSSIBLE RISKS
- Peptide overcapacity (FY29+)
- Biotech funding reversing just as new capacity comes online
- Debt-funded capex ahead of revenue
- Counterparty risk on take-or-pay deals
- FDA observations at key sites
- Middle East–driven solvent and logistics costs
FOCUS ON:
- Commercial small-molecule CDMO with operating leverage: the nearest earnings
- ADC/HPAPI: few credible players, proven demand
- Peptides, selectively: full-API, backward-integrated players with dated validation timelines
- Fermentation: wait for the first commercial batch before underwriting it
CATALYSTS TO WATCH (APR 2027–MAR 2028)
- Symbiotec: alt-protein commercial batches (Q1), first DCV ANDA approval (late CY27), insulin sales
- Laurus: LB-4 supplies, KRKA JV start, peptide validation campaigns
- Sai: second 225 KL Bidar block (Q3)
- Piramal: full Lexington sterile fill-finish expansion
- Shilpa: rotigotine EU launch, nivolumab EU filing, first late-stage CDMO programme commercial
BOTTOM LINE
The demand story is now consensus. The next two years will be decided by utilisation, execution and balance sheets.
Valuations look high for obvious reason, but no one can deny that the opportunity size as well as the rate of growth here is massive. So keep reading and hunting in this space. We might still have just seen just the trailer here but the ride will be lumpy so either stay put for longer or position yourselves accordingly when the weak hands go out.
Disc: Educational only, not investment advice
Prince | Accidental Investor 🇮🇳 retweeted
Framing Business Uncertainty
Page 132
#PIIndustries
Written “ex ante” in 2023
Released “ex ante” early 2024
Today is all “ex post”
Warm regards 🎶🍿
Prince | Accidental Investor 🇮🇳 retweeted
Replying to @dinamaniaec
Mere paas “ISI” mark nahi. Approved writer nahi hoon. Sirf approved pressure cooker hi seetee Baja sake hai 😈
Prince | Accidental Investor 🇮🇳 retweeted
Diwali live session on Substack.
Nov 7, 21:00 IST / 15:30 GMT.
Open to all subscribers, free included.
Prince | Accidental Investor 🇮🇳 retweeted
Replying to @ItheHAK @ParikshitBhand6
“ISI” mark hai? Approved ho? Sirf approved pressure cooker hi seetee Baja sake hai 😈
Prince | Accidental Investor 🇮🇳 retweeted
Join today. Your price is grandfathered for life.
convexia.in/subscribe
















